Autolus Therapeutics Plc - Understand $autl stock

$AUTL Market Cap: $875.3 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$10.09M

TTM

Gross Margin

Net Earnings

-$270.2M

TTM

Current Assets

$718.1M

Q3 2024

Current Liabilities

$52.47M

Q3 2024

Current Ratio

1368.51%

Q3 2024

Total Assets

$827.5M

Q3 2024

Total Liabilities

$350.5M

Q3 2024

Book Value

$477.0M

Q3 2024

Cash

$657.1M

Q3 2024

P/E

-3.239

Nov 13, 2024 EST

Free Cash Flow

-$119.3M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$1.698M	$6.360M	$2.330M	$1.720M	$2.910M	$300.0K	$1.690M	$1.210M	$1.210M
YoY Change	-73.3%	172.96%	35.47%	-40.89%	870.0%	-82.25%	39.67%	0.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$1.698M	$6.360M	$2.330M	$1.720M	$2.910M	$300.0K	$1.690M	$1.210M	$1.210M
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Selling, General & Admin	$54.91M	$36.67M	$38.00M	$41.45M	$43.83M	$7.590M	$9.100M	$5.150M	$5.150M
YoY Change	49.74%	-3.5%	-8.32%	-5.43%	477.47%	-16.59%	76.7%	0.0%
% of Gross Profit
Research & Development	$130.5M	$142.0M	$128.7M	$128.4M	$101.0M	$17.71M	$16.01M	$10.44M	$10.44M
YoY Change	-8.11%	10.37%	0.19%	27.09%	470.53%	10.62%	53.35%	0.0%
% of Gross Profit
Depreciation & Amortization	$6.565M	$7.422M	$8.458M	$5.660M	$4.610M	$650.0K	$480.0K	$1.010M	$1.010M
YoY Change	-11.55%	-12.25%	49.43%	22.78%	609.23%	35.42%	-52.48%	0.0%
% of Gross Profit
Operating Expenses	$130.5M	$142.0M	$166.7M	$169.9M	$144.9M	$25.31M	$25.11M	$15.59M	$15.59M
YoY Change	-8.11%	-14.8%	-1.89%	17.25%	472.38%	0.8%	61.06%	0.0%
Operating Profit	-$179.7M	-$168.0M	-$165.0M	-$168.1M
YoY Change	6.94%	1.85%	-1.87%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Interest Expense	$45.07M	$8.905M	-$3.143M	$540.0K	$2.540M	$660.0K	$80.00K	$80.00K	$80.00K
YoY Change	406.09%	-383.33%	-682.04%	-78.74%	284.85%	725.0%	0.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	-$28.70M	-$5.159M	$2.155M	$1.350M	$4.510M	$1.100M	-$50.00K	-$30.00K	-$30.00K
YoY Change	456.33%	-339.4%	59.63%	-70.07%	310.0%	-2300.0%	66.67%	0.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Pretax Income	-$208.4M	-$173.2M	-$166.0M	-$166.3M	-$139.0M	-$23.25M	-$23.38M	-$14.33M	-$14.33M
YoY Change	20.32%	4.35%	-0.16%	19.6%	497.89%	-0.56%	63.15%	0.0%
Income Tax	-$19.00K	-$24.37M	-$23.89M	-$24.16M	-$15.16M	-$2.610M	-$3.650M	-$1.780M	-$1.780M
% Of Pretax Income
Net Earnings	-$208.4M	-$148.8M	-$142.1M	-$142.1M	-$123.9M	-$20.65M	-$19.73M	-$12.55M	-$12.55M
YoY Change	40.01%	4.75%	0.0%	14.73%	499.76%	4.66%	57.21%	0.0%
Net Earnings / Revenue	-12272.26%	-2340.24%	-6098.54%	-8261.05%	-4256.01%	-6883.33%	-1167.46%	-1037.19%	-1037.19%
Basic Earnings Per Share	-$1.20	-$1.57	-$1.97	-$2.76
Diluted Earnings Per Share	-$1.20	-$1.57	-$1.971M	-$2.756M	-$2.876M	-$524.5K	-$508.6K	-$323.5K	-$323.5K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Short-Term Investments	$239.6M	$382.4M	$310.3M	$153.3M	$210.6M	$217.5M	$137.1M	$28.10M	$28.10M
YoY Change	-37.36%	23.23%	102.44%	-27.21%	-3.17%	58.64%	387.9%	0.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$11.19M	$14.36M	$10.36M	$14.00M	$8.100M	$2.200M	$700.0K	$700.0K	$700.0K
YoY Change	-22.04%	38.55%	-25.97%	72.84%	268.18%	214.29%	0.0%	0.0%
Inventory
Prepaid Expenses
Receivables	$109.0K	$121.0K
Other Receivables	$24.43M	$28.86M
Total Short-Term Assets	$275.3M	$425.8M	$347.0M	$197.0M	$249.3M	$233.0M	$142.5M	$30.90M	$30.90M
YoY Change	-35.34%	22.72%	76.12%	-20.98%	7.0%	63.51%	361.17%	0.0%
Property, Plant & Equipment	$95.65M	$58.42M	$52.32M	$89.70M	$51.60M	$20.00M	$6.200M	$3.300M	$3.300M
YoY Change	63.74%	11.67%	-41.68%	73.84%	158.0%	222.58%	87.88%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.426M	$6.084M	$6.227M	$7.400M	$2.500M	$1.300M
YoY Change	-27.25%	-2.3%	-15.85%	196.0%	92.31%
Total Long-Term Assets	$100.1M	$64.50M	$58.61M	$97.20M	$54.20M	$21.20M	$6.200M	$3.300M	$3.300M
YoY Change	55.15%	10.06%	-39.7%	79.34%	155.66%	241.94%	87.88%	0.0%
Total Assets	$375.4M	$490.3M	$405.6M	$294.2M	$303.5M	$254.2M	$148.7M	$34.20M	$34.20M
YoY Change
Accounts Payable	$103.0K	$531.0K	$431.0K	$2.300M	$1.100M	$2.000M	$1.900M	$1.400M	$1.400M
YoY Change	-80.6%	23.2%	-81.26%	109.09%	-45.0%	5.26%	35.71%	0.0%
Accrued Expenses	$44.10M	$45.44M	$27.97M	$30.90M	$22.80M	$18.00M	$2.500M	$1.000M	$1.000M
YoY Change	-2.95%	62.47%	-9.48%	35.53%	26.67%	620.0%	150.0%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$44.74M	$46.37M	$28.55M	$33.60M	$25.00M	$21.10M	$5.000M	$2.700M	$2.700M
YoY Change	-3.51%	62.4%	-15.03%	34.4%	18.48%	322.0%	85.19%	0.0%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$219.2M	$145.2M	$63.69M	$50.60M	$23.70M	$500.0K	$1.000M	$800.0K	$800.0K
YoY Change	50.91%	128.04%	25.87%	113.5%	4640.0%	-50.0%	25.0%	0.0%
Total Long-Term Liabilities	$219.2M	$145.2M	$63.69M	$50.60M	$23.70M	$500.0K	$1.000M	$800.0K	$800.0K
YoY Change	50.91%	128.04%	25.87%	113.5%	4640.0%	-50.0%	25.0%	0.0%
Total Liabilities	$263.9M	$191.6M	$92.24M	$84.20M	$48.70M	$21.60M	$6.100M	$3.500M	$3.500M
YoY Change	37.74%	107.72%	9.55%	72.9%	125.46%	254.1%	74.29%	0.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	173.9M shares	94.99M shares	72.08M shares	51.56M shares
Diluted Shares Outstanding	173.9M shares	94.99M shares	72.08M shares	51.56M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $875.26 Million

About Autolus Therapeutics PLC

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The company is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. The company has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Industry: Biological Products, (No Diagnostic Substances) Peers: Achilles Therapeutics PLC Adaptimmune Therapeutics PLC Centessa Pharmaceuticals PLC Compass Pathways PLC Barinthus Biotherapeutics PLC